You are here

peanut allergy

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Endpoints

Flag link:

DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK

DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK

Endpoints

DBV Technologies

Flag link:

Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate

Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate

Pharma Times

Allergy Therapeutics

Flag link:

Why DBV Technologies Stock Is Soaring Today

Why DBV Technologies Stock Is Soaring Today

Motley Fool

DBV Technologies

Flag link:

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Endpoints

Flag link:

Nestle pays $2 billion to secure Aimmune’s allergy treatment

Nestle pays $2 billion to secure Aimmune’s allergy treatment

CNBC

Flag link:

Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

BioSpace

DBV Technologies

Flag link:

With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash

With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash

Xconomy

DBV Technologies

Flag link:

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

Motley Fool

DBV Technologies

Aimmune Therapeutics

Flag link:

In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions

In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions

Endpoints

DBV Technologies

Flag link:

DBV's peanut prevention patch approaches key stage of approval process

DBV's peanut prevention patch approaches key stage of approval process

Endpoints

DBV Technologies

Flag link:

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

Motley Fool

DBV Technologies

Flag link:

Aimmune wins approval for peanut immunotherapy, charges 10k+

Aimmune wins approval for peanut immunotherapy, charges 10k+

Endpoints

Flag link:

FDA decision nears on Aimmune's contested peanut allergy drug

FDA decision nears on Aimmune's contested peanut allergy drug

BioPharma Dive

DBV Technologies

Flag link:

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Motley Fool

Aimmune Therapeutics

Flag link:

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Fierce Biotech

Stanford University

Flag link:

Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches

Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches

BioSpace

Aimmune Therapeutics

real world data

Flag link:

DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy

Pharmaceutical Business Review

DBV Technologies

Flag link:

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug

NPR

Aimmune Therapeutics

Flag link:

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Biopharma Dive

Flag link:

Pages